P-selectin

Crizanlizumab helps prevent pain crises in sickle cell diseaseIn patients with sickle cell disease, therapy with crizanlizumab, an antibody against the adhesion molecule P-selectin, resulted in a significantly lower rate of sickle cell-related pain crises than placebo, a trial in 198 patients aged from 16 to 65 years showed.